130 related articles for article (PubMed ID: 37363969)
1. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
[TBL] [Abstract][Full Text] [Related]
2. Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
Landau H; Wood K; Chung DJ; Koehne G; Lendvai N; Hassoun H; Lesokhin A; Hoover E; Zheng J; Devlin SM; Giralt S
Leuk Lymphoma; 2016 Aug; 57(8):1781-5. PubMed ID: 26758672
[TBL] [Abstract][Full Text] [Related]
3. Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single-centre, retrospective review in the Australian setting.
Tan XN; Yew CY; Ragg SJ; Harrup RA; Johnston AM
Intern Med J; 2022 Jul; 52(7):1242-1250. PubMed ID: 33949777
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.
Jandial A; Lad D; Jain A; Khadwal A; Singh C; Prakash G; Suri V; Sreedharanunni S; Sachdeva MUS; Ray P; Varma N; Varma S; Malhotra P
Transpl Infect Dis; 2023 Oct; 25(5):e14123. PubMed ID: 37573150
[TBL] [Abstract][Full Text] [Related]
5. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
[TBL] [Abstract][Full Text] [Related]
7. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
8. Pilot Trial of Homebound Hematopoietic Cell Transplantation.
Landau HJ; Orlando E; Rodriguez ES; Applebaum A; Mitchell HR; Peled JU; Khan N; Funnell T; Chung D; Scordo M; Shah GL; LeStrange NJ; Hambright KA; McElrath CM; Cazeau N; Devlin SM; Perales MA; Giralt SA
Transplant Cell Ther; 2022 Dec; 28(12):832.e1-832.e7. PubMed ID: 36182105
[TBL] [Abstract][Full Text] [Related]
9. Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.
Paul TM; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Nasta SD; Loren A; Frey N; Perl A; Cohen AD; Weiss BM; Stadtmauer EA; Vogl DT
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):536-40. PubMed ID: 26141214
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
[TBL] [Abstract][Full Text] [Related]
11. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant.
Al Saleh AS; Sidiqi MH; Lee J; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Skaer CA; Wittwer SK; Wolf RC; Hogan WJ; Kumar SK; Jacob E; Gertz MA
Bone Marrow Transplant; 2020 Nov; 55(11):2132-2137. PubMed ID: 32358546
[TBL] [Abstract][Full Text] [Related]
12. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the Utility of Granulocyte Colony-Stimulating Factor Post-Autologous Hematopoietic Stem Cell Transplantation for Outpatient-Based Transplantations.
Portuguese AJ; Holmberg L; Hill GR; Lee SJ; Green DJ; Mielcarek M; Gooley T; Yeh AC
Transplant Cell Ther; 2023 Nov; 29(11):696.e1-696.e7. PubMed ID: 37634844
[TBL] [Abstract][Full Text] [Related]
14. Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant.
Watson AN; Shah SA; Shalhoub SD; Piedra KM; Komanduri KV; Kwon D; Pereira DL
J Oncol Pharm Pract; 2023 Sep; 29(6):1398-1403. PubMed ID: 36245321
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Viola A; Delia R; Carbone A; Celentano M
Hematol Oncol; 2011 Sep; 29(3):139-43. PubMed ID: 21922508
[TBL] [Abstract][Full Text] [Related]
16. A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation.
Grosso D; Leiby B; Wilde L; Carabasi M; Filicko-O'Hara J; O'Hara W; Wagner JL; Mateja G; Alpdogan O; Binder A; Kasner M; Keiffer G; Klumpp T; Martinez UO; Palmisiano N; Porcu P; Gergis U; Flomenberg N
Transplant Cell Ther; 2022 Dec; 28(12):831.e1-831.e7. PubMed ID: 36167307
[TBL] [Abstract][Full Text] [Related]
17. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment.
Clemmons AB; Anderegg S
J Oncol Pharm Pract; 2017 Jul; 23(5):384-388. PubMed ID: 27000280
[TBL] [Abstract][Full Text] [Related]
18. Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK; Harvey RD
Pharmacotherapy; 2022 Mar; 42(3):233-240. PubMed ID: 35122287
[TBL] [Abstract][Full Text] [Related]
19. Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation.
Khouri J; Rybicki L; Majhail NS; Kalaycio M; Pohlman B; Hill B; Jagadeesh D; Dean R; Hamilton B; Sobecks R; Koo A; Liu H
J Clin Apher; 2019 Dec; 34(6):638-645. PubMed ID: 31381194
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.
Cox JE; Campos S; Wu J; May R; Liu H; Ramos CA; Carrum G; Heslop HE; Brenner MK; Kamble RT
Bone Marrow Transplant; 2014 Feb; 49(2):219-22. PubMed ID: 24096822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
